Pointcross Life Sciences

Executive Summary

PointCross Life Sciences is a Boston-based technology company that streamlines clinical and nonclinical study data management for the biopharma industry through its AI-enhanced Clinical Data Automation Platform (CDAP), XBIOM™. The platform automates the generation of regulatory-compliant datasets (SEND, SDTM, ADaM) and provides real-time interim monitoring for trials, significantly reducing timelines and costs for sponsors and CROs. Founded in 2016, the company addresses a critical bottleneck in drug development—data standardization and submission readiness—where errors or delays can lead to costly setbacks. As regulatory agencies increasingly demand high-quality, machine-readable data, PointCross's automation and AI capabilities position it as a key enabler for efficient clinical data management. The company operates in a growing market driven by the rise of complex trial designs and the need for faster submission cycles. While specific financials are not disclosed, the platform’s utility across therapeutic areas and its potential to integrate with existing eClinical systems suggest strong adoption prospects. PointCross is well-positioned to capture market share as biopharma companies seek to modernize their data operations and reduce manual effort. The company's focus on compliance and speed aligns with industry trends toward digitalization and AI-driven efficiency.

Upcoming Catalysts (preview)

• Q3 2026Major pharma or CRO partnership for XBIOM platform60% success
• Q4 2026Launch of new AI-driven module for real-time data quality checks70% success
• TBDFDA recognition or certification for SEND/SDTM automation process40% success